All In Biotech

Drug Trial Radar · NCT00223964

Study of the Efficacy of Two Doses of Ferrlecit in the Treatment of Iron Deficiency in Pediatric Hemodialysis Patients

Randomized Double-Blind Parallel Group MultiCenter Study of the Efficacy of Two Doses of Ferrlecit® in Treatment of Iron Deficiency in Pediatric Hemodialysis Patients Receiving Epoetin.

Last checked: Nov 20, 2026Latest source record: Aug 14, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

59

Actual

Start

Jun 2003

Primary completion

Oct 2003

Sponsor

Lead sponsor
Watson PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Sep 22, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 2 years, up to 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a multi-center study in iron-deficient pediatric hemodialysis patients, whose legal guardian had provided signed informed consent and satisfied the inclusion and exclusion criteria.

Conditions

  • Anemia

Interventions

  • Ferrlecit (sodium ferric gluconate complex in sucrose injection)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Demonstrate and compare effectiveness of two Ferrlecit® doses in increasing hemoglobin in iron-deficient pediatric hemodialysis patients requiring repletion iron therapy.Time frame: 2 weeks

Locations

24 sites in 5 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Los Angeles, California

  • Site not named

    San Diego, California

  • Site not named

    Stanford, California

  • Site not named

    Boston, Massachusetts

  • Site not named

    Kansas City, Missouri

  • Site not named

    The Bronx, New York

  • Site not named

    Seattle, Washington

  • Site not named

    Aruascalientes, Mexico

  • Site not named

    Mexico City, Mexico

  • Site not named

    Bialystok, Poland

  • Site not named

    Gdansk, Poland

  • Site not named

    Krakow, Poland

  • Site not named

    Lodz, Poland

  • Site not named

    Lublin, Poland

  • Site not named

    Szczecin, Poland

  • Site not named

    Torum, Poland

  • Site not named

    Wroclaw, Poland

  • Site not named

    Zabrze, Poland

  • Site not named

    Bashkortostan, Russia

  • Site not named

    Moscow, Russia

  • Site not named

    Saint Petersburg, Russia

  • Site not named

    Tartarstan, Russia

  • Site not named

    Belgrade, Serbia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.